Clinical DataThe updated Ph 2a data continues to demonstrate an improved clinical profile, both on efficacy and safety, for the combo in 1L PDAC patients compared to GnP alone.
Management ExpertiseThe appointment of Dr. Igor Matushansky as the CMO brings extensive oncology drug development expertise to the company.
Strategic PartnershipsA second clinical supply agreement this year with Regeneron for Libtayo further strengthens the company's strategic partnerships.